Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 248

1.

JAK/STAT signaling in hematological malignancies.

Vainchenker W, Constantinescu SN.

Oncogene. 2013 May 23;32(21):2601-13. doi: 10.1038/onc.2012.347. Epub 2012 Aug 6. Review.

PMID:
22869151
2.

JAK/STAT signal transduction: regulators and implication in hematological malignancies.

Valentino L, Pierre J.

Biochem Pharmacol. 2006 Mar 14;71(6):713-21. Epub 2006 Jan 19. Review.

PMID:
16426581
3.

Mining for JAK-STAT mutations in cancer.

Constantinescu SN, Girardot M, Pecquet C.

Trends Biochem Sci. 2008 Mar;33(3):122-31. doi: 10.1016/j.tibs.2007.12.002. Review.

PMID:
18291658
4.

The JAK-STAT pathway: a therapeutic target in hematological malignancies.

Ferrajoli A, Faderl S, Ravandi F, Estrov Z.

Curr Cancer Drug Targets. 2006 Dec;6(8):671-9. Review.

PMID:
17168672
5.

JAK2 inhibitors in the treatment of myeloproliferative neoplasms.

Tibes R, Bogenberger JM, Geyer HL, Mesa RA.

Expert Opin Investig Drugs. 2012 Dec;21(12):1755-74. doi: 10.1517/13543784.2012.721352. Epub 2012 Sep 19. Review.

PMID:
22991927
6.

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.

Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, DeAngelo DJ, Clark JJ, Lee SJ, Golub TR, Wadleigh M, Gilliland DG, Levine RL.

PLoS Med. 2006 Jul;3(7):e270.

7.

[Research advances in the role of JAK2 mutations in acute leukemia].

Zhang HY, Zhai XW.

Zhongguo Dang Dai Er Ke Za Zhi. 2015 Jun;17(6):644-9. Review. Chinese.

8.

RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis.

Winter PS, Sarosiek KA, Lin KH, Meggendorfer M, Schnittger S, Letai A, Wood KC.

Sci Signal. 2014 Dec 23;7(357):ra122. doi: 10.1126/scisignal.2005301.

9.

JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.

Springuel L, Renauld JC, Knoops L.

Haematologica. 2015 Oct;100(10):1240-53. doi: 10.3324/haematol.2015.132142. Review.

10.

Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.

Bhagwat N, Levine RL, Koppikar P.

Int J Hematol. 2013 Jun;97(6):695-702. doi: 10.1007/s12185-013-1353-5. Epub 2013 May 14. Review.

PMID:
23670175
11.

Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.

Hornakova T, Springuel L, Devreux J, Dusa A, Constantinescu SN, Knoops L, Renauld JC.

Haematologica. 2011 Jun;96(6):845-53. doi: 10.3324/haematol.2010.036350. Epub 2011 Mar 10.

12.

Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers.

Hornakova T, Staerk J, Royer Y, Flex E, Tartaglia M, Constantinescu SN, Knoops L, Renauld JC.

J Biol Chem. 2009 Mar 13;284(11):6773-81. doi: 10.1074/jbc.M807531200. Epub 2009 Jan 12.

13.

JAK and MPL mutations in myeloid malignancies.

Tefferi A.

Leuk Lymphoma. 2008 Mar;49(3):388-97. doi: 10.1080/10428190801895360. Review.

PMID:
18297515
14.

Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.

Losdyck E, Hornakova T, Springuel L, Degryse S, Gielen O, Cools J, Constantinescu SN, Flex E, Tartaglia M, Renauld JC, Knoops L.

J Biol Chem. 2015 Nov 27;290(48):29022-34. doi: 10.1074/jbc.M115.670224. Epub 2015 Oct 7.

15.

JAK2 the future: therapeutic strategies for JAK-dependent malignancies.

LaFave LM, Levine RL.

Trends Pharmacol Sci. 2012 Nov;33(11):574-82. doi: 10.1016/j.tips.2012.08.005. Epub 2012 Sep 17. Review.

PMID:
22995223
16.

Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.

Chachoua I, Pecquet C, El-Khoury M, Nivarthi H, Albu RI, Marty C, Gryshkova V, Defour JP, Vertenoeil G, Ngo A, Koay A, Raslova H, Courtoy PJ, Choong ML, Plo I, Vainchenker W, Kralovics R, Constantinescu SN.

Blood. 2016 Mar 10;127(10):1325-35. doi: 10.1182/blood-2015-11-681932. Epub 2015 Dec 14.

17.

Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.

Mughal TI, Girnius S, Rosen ST, Kumar S, Wiestner A, Abdel-Wahab O, Kiladjian JJ, Wilson WH, Van Etten RA.

Leuk Lymphoma. 2014 Sep;55(9):1968-79. doi: 10.3109/10428194.2013.863307. Epub 2014 Feb 17. Review.

18.

JAK2 V617F-dependent upregulation of PU.1 expression in the peripheral blood of myeloproliferative neoplasm patients.

Irino T, Uemura M, Yamane H, Umemura S, Utsumi T, Kakazu N, Shirakawa T, Ito M, Suzuki T, Kinoshita K.

PLoS One. 2011;6(7):e22148. doi: 10.1371/journal.pone.0022148. Epub 2011 Jul 18.

19.

JAK2 inhibition for the treatment of hematologic and solid malignancies.

Harry BL, Eckhardt SG, Jimeno A.

Expert Opin Investig Drugs. 2012 May;21(5):637-55. doi: 10.1517/13543784.2012.677432. Review.

PMID:
22493978
20.

JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.

TreliƄski J, Robak T.

Curr Med Chem. 2013;20(9):1147-61.

PMID:
23317159

Supplemental Content

Support Center